Hikma in-licenses inhaled insulin for MENA; Advaxis and FusionVax Asia deal

23 April 2013

Jordan-based Hikma Pharmaceuticals (LSE: HIK) has signed a licensing and distribution agreement with USA-based Dance Biopharm for its proprietary inhaled insulin product, Dance 01, for the Middle East and Africa. Dance 01 is currently under development for the treatment of patients with diabetes, with Phase III studies expected to begin next year.

Under the terms of the accord, Hikma will have the exclusive rights to register, market and distribute Dance 01 across the Middle East and Africa. The agreement will initially leverage Hikma’s strong local presence and regulatory expertise in the Middle East and North Africa (MENA), with over 1,600 sales and marketing representatives across the region.

MENA private market for diabetes products worth over $668 million

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK